Citigroup Maintains Neutral on BridgeBio Pharma, Raises Price Target to $93
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.
Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises the price target from $82 to $93.